INTRODUCTION AND OBJECTIVES: Despite its utility in the non-neurogenic population, limited objective data exists regarding the efficacy of autologous pubovaginal sling (PVS) placement for management of urinary incontinence in patients with neurogenic bladder (NGB). We aim to assess long-term outcomes of PVS in neurogenic urinary incontinence.
METHODS: This is a retrospective review of patients with NGB who received an autologous PVS from January 1st, 2000 -December 31st, 2017 at a single center. Patients with NGB undergoing PVS were identified from electronic medical record using CPT codes. Subjective and objective outcomes were collected including American Urologic Association Symptom Index (AUA-SI) and Incontinence Symptom Index (ISI).
RESULTS: Thirty-one women with NGB receiving PVS were included. Patients had a mean age of 55AE16 years and BMI of 28.7AE7 kg/m2. Six patients (19.3%) had previously failed PVS. Preoperatively, patients were managed with clean intermittent catheterization (CIC) (64.5%), urethral catheter (16.1%), ileovesicostomy (6.4%), and suprapubic tube (SPT) (3.2% (Figure 1 ). Four women underwent ileal conduit for persistent incontinence.
CONCLUSIONS: While most patients continued to have incontinence after PVS, significant improvement in objective measures was noted. This data is limited by a small retrospective nature of the review and further studies are needed to understand the role of PVS as a treatment option for urinary incontinence in NGB.
Source of Funding: None

PD02-04 THE USE OF URETHRAL SLINGS TO TREAT INCONTINENCE IN ELDERLY WOMEN; IS IT SAFE?
Valary Raup*, Alexandra Berger, Julie Szymaniak, Steven Chang, Elodi Dielubanza, Boston, MA INTRODUCTION AND OBJECTIVES: Urethral slings are a durable treatment for stress urinary incontinence. However, there is a paucity of data on the use of slings in the very elderly. Here, we sought to evaluate the use of urethral slings to treat incontinence in female octogenarians.
METHODS: The Premier Hospital Database (2003-2015) was queried using International Classification of Diseases (ICD-9) procedural codes (CPT) codes for urethral sling procedures. Slings were classified by type (retropubic, transobturator, or single incision). Advanced age was defined as 80 years old. Prolonged length of stay (pLOS, 1day), prolonged operative time (pOT, 90 minutes), major postoperative complications, sling type, and excess cost ($5397) were analyzed. Each threshold represents 75th percentile. Chi-squared and logistic regressions were used for analysis.
RESULTS: A total of 143,474 women who underwent urethral sling placement were identified, with a median age of 55 years (25-85). Of these, 59,212 were 80 years old (41.3%). There was no association between advanced age and sling type (p[0.142). Sling placement was associated with an overall post-operative complication rate of 0.35% (503/143,474). Age 80 was associated with a higher rate of major post-operative complications (OR 5.99, 1.72% vs. 0.29%, p<0.0001), pOT (27.2% vs. 20.3%, p<0.0001), pLOS (32.7% vs. 21.6% p<0.0001), and excess cost (35.5% vs 24.6%, <0.0001). When controlled for pOT and Charleson Comorbidity Index (CCI), age was still associated with increased rate of major complications (OR 3.44, p<0.0001).
CONCLUSIONS: While octogenarians are more likely than younger women to experience major complications after sling placement, the observed rate was only 1.7%.
In our nationally-representative sample, age !80 was also associated with pOT, pLOS, and excess cost. Thus, urethral sling should be considered for well-selected octogenarians suffering from stress incontinence, but every effort should be made to medically optimize these patients pre-operatively, and patients should be counseled appropriately on their increased risk. METHODS: This is a planned secondary analysis of a prospective study comparing SIS to TMUS. Primary study aim was to compare efficacy and safety using a noninferiority(NI) design to detect 15% difference in treatment success and 10% difference in safety. Treatment success was defined by composite objective measure(negative cough stress test) and subjective improvement in stress urinary incontinence(UI) using Patient Global Impression of Improvement (PGI-I) at 36 months. We collected validated PROs at baseline, 6,12,18,24, and 36 months to quantify UI severity (Incontinence Severity Index(ISI)), symptom bother (Urogenital Distress Inventory(UDI-6)), disease-specific quality of life (QoL) impact (Urinary Impact Questionnaire(UIQ-7)), and generic QoL impact (PGI-I). PROs were analyzed within treatment groups as well as between groups.
RESULTS: Baseline characteristics were balanced after propensity score stratification (N[141 SIS, N[140 TMUS [-9.3%, 6 .6%], demonstrating NI at the pre-set margin. In both groups, serious adverse event (AE) rate (meshrelated complications) was 0.7%, and AE rates (dyspareunia, pelvic pain, and urinary retention) were low. Participants had significant improvement in UI severity, disease-specific symptom bother and QoL impact, and improvements persisted through the study. PROs Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e63
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